Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LY3435151 |
| Synonyms | |
| Therapy Description |
LY3435151 is an antibody that targets and binds to CD226, a cell surface glycoprotein, potentially leading to the activation of the antitumor immune response (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LY3435151 | LY 3435151|LY-3435151 | LY3435151 is an antibody that targets and binds to CD226, a cell surface glycoprotein, potentially leading to the activation of the antitumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04099277 | Phase I | LY3435151 + Pembrolizumab LY3435151 | A Study of LY3435151 in Participants With Solid Tumors | Terminated | USA | 1 |